anticoagulant activity may be seen with androgens; therefore, more frequent monitoring of international normalized ratio (inr) and prothrombin time are recommended in patients taking warfarin, especially at the initiation and termination of androgen therapy. 7.3 corticosteroids the concurrent use of testosterone with corticosteroids may result in increased fluid retention and requires careful monitoring particularly in patients with cardiac, renal, or hepatic disease. 7.4 medications that may also increase blood pressure some prescription medications and nonprescription analgesic and cold medications contain drugs known to increase blood pressure. concomitant administration of these medications with kyzatrex™ may lead to additional increases in blood pressure [see warnings and precautions (5.1) ].

for conditions associated with a deficiency or absence of endogenous testosterone ( 1 ). limitations of use: safety and efficacy of kyzatrex™ in males less than 18 years old have not been established ( 1 , 8.4 ). limitations of use safety and efficacy of kyzatrex™ in males less than 18 years old have not been established [see use in specific populations (8.4) ] .

estosterone concentration ( 5.6 ). potential for adverse effects on spermatogenesis : kyzatrex™ may cause azoospermia ( 5.8 ). edema : edema, with or without congestive heart failure (chf), may occur in patients with pre-existing cardiac, renal, or hepatic disease. discontinue kyzatrex™ and initiate appropriate workup ( 5.10 ). sleep apnea : kyzatrex™ may potentiate sleep apnea in those with risk factors ( 5.11 ) lipid changes : kyzatrex™ may affect serum lipid profile. monitor patient lipid concentrations periodically; if necessary, adjust dosage of lipid lowering drug(s) or discontinue kyzatrex™ ( 5.13 ). 5.1 increase in blood pressure in study mrs-tu-2019ext, kyzatrex™ increased 24-hour average systolic blood pressure (sbp) measured by ambulatory blood pressure monitoring (abpm) by 1.7 mmhg from baseline after 4 months of treatment and 1.8 mmhg from baseline after 6 months of treatment [see adverse reactions (6.1) ] . three percent of kyzatrex™-treated patients were started on antihypertensive medications during the 6-month trial. a history of antihypertensive treatment and diabetes mellitus at baseline were significant factors related to ambulatory sbp increases [see adverse reactions (6.1) ] . blood pressure (bp) increases can increase the risk of major adverse cardiovascular events (mace), with greater risk in patients with established cardiovascular disease or risk factors for cardiovascular disease. in some patients, the increase in bp with kyzatrex™ may be too small to detect but can still increase the risk for mace. before initiating kyzatrex™, consider the patient's baseline cardiovascular risk and ensure blood pressure is adequately controlled. check bp periodically after initiating kyzatrex™ or increasing the dose and thereafter. treat new-onset hypertension or exacerbations of pre-existing hypertension. re-evaluate whether the benefits of continued treatment with kyzatrex™ outweigh its risks in patients who develop cardiovascular risk factors or cardiovascular disease. 5.2 polycythemia androgens, including kyzatrex™, can cause increase in hemoglobin or hematocrit, reflective of increase in red blood cell mass. check hematocrit prior to initiating kyzatrex™. an increase in red blood cell mass may increase the risk of thromboembolic events [see warnings and precautions (5.5) ] . evaluate hematocrit approximately every 3 months while the patient is on kyzatrex™. if hematocrit becomes elevated, stop kyzatrex™ until the hematocrit decreases to an acceptable concentration. if kyzatrex™ is restarted and again causes hematocrit to become elevated, permanently discontinue kyzatrex™. 5.3 cardiovascular risk long-term clinical safety trials have not been conducted to assess the cardiovascular outcomes of testosterone replacement therapy in men. to date, epidemiologic studies and randomized controlled trials have been inconclusive for determining the risk of mace, such as non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death, with testosterone use compared to non-use. some studies have reported an increased risk of mace in association with use of testosterone replacement therapy in men. kyzatrex™ can cause bp increases that can increase the risk of mace [see warnings and precautions (5.1) ] . patients should be informed of this possible risk when deciding whether to use or to continue to use kyzatrex™. 5.4 worsening of benign prostatic hyperplasia (bph) and potential risk of prostate cancer patients with bph who are treated with androgens are at an increased risk for worsening of signs and symptoms of bph. monitor patients with bph for worsening signs and symptoms. patients treated with androgens may be at increased risk for prostate cancer. evaluate patients for prostate cancer prior to initiating and during treatment with androgens [see contraindications (4) ] . 5.5 venous thromboembolism there have been post-marketing reports of venous thromboembolic events, including deep vein thrombosis (dvt) and pulmonary embolism (pe), in patients using testosterone replacement products such as kyzatrex™. evaluate patients who report symptoms of pain, edema, warmth, and erythema in the lower extremity for dvt and those who present with acute shortness of breath for pe. if a venous thromboembolic event is suspected, discontinue kyzatrex™ and initiate appropriate workup and management [see adverse reactions (6.2) ]. 5.6 abuse of testosterone and monitoring of testosterone concentrations testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. anabolic androgenic steroid abuse can lead to serious cardiovascular and psychiatric adverse reactions [see drug abuse and dependence (9) ]. if testosterone abuse is suspected, check testosterone concentrations to ensure they are within therapeutic range [see dosage and administration (2.2) ]. testosterone levels may remain in the normal or subnormal range in men abusing synthetic testosterone derivatives. counsel patients concerning the serious adverse reactions associated with abuse of testosterone and anabolic androgenic steroids. also consider the possibility of testosterone and anabolic androgenic steroid abuse in suspected patients who present with serious cardiovascular or psychiatric adverse events. 5.7 not for use in women due to lack of controlled studies in women and potential virilizing effects, kyzatrex™ is not indicated for use in women [see contraindications (4) and use in specific populations (8.1 , 8.2) ]. 5.8 potential for adverse effects on spermatogenesis with large doses of exogenous androgens, including kyzatrex™, spermatogenesis may be suppressed through feedback inhibition of pituitary fsh, possibly leading to adverse effects on semen parameters including sperm count [see use in specific populations (8.3) ]. inform patients of this possible risk when deciding whether to use or to continue to use kyzatrex™. 5.9 hepatic adverse effects kyzatrex™ is not a 17-alpha-alkyl androgen and is not known to cause hepatic adverse effects. however, prolonged use of high doses of orally active 17-alpha-alkyl androgens (e.g., methyltestosterone) has been associated with serious hepatic adverse effects (peliosis hepatis, hepatic neoplasms, cholestatic hepatitis, and jaundice). peliosis hepatis can be a life-threatening or fatal complication. long-term therapy with intramuscular testosterone enanthate has produced multiple hepatic adenomas. patients should be instructed to report any signs or symptoms of hepatic dysfunction (e.g., jaundice). if these occur, promptly discontinue kyzatrex™ while the cause is evaluated. 5.10 edema androgens, including kyzatrex™, may promote retention of sodium and water. edema, with or without congestive heart failure, may be a serious complication in patients with pre-existing cardiac, renal, or hepatic disease [see adverse reactions (6.1) ] . in addition to discontinuation of the drug, diuretic therapy may be required. 5.11 sleep apnea the treatment of hypogonadal men with testosterone may potentiate sleep apnea in some patients, especially those with risk factors such as obesity or chronic lung disease. 5.12 gynecomastia gynecomastia may develop and persist in patients being treated for hypogonadism. 5.13 lipid changes in clinical trials, patients receiving kyzatrex™ experienced reductions in lipid parameters, including total cholesterol, ldl cholesterol, hdl cholesterol, and triglycerides [see adverse reactions (6.1) ] . changes in the serum lipid profile may require dose adjustment of lipid lowering drugs or discontinuation of testosterone therapy. monitor the lipid profile periodically, particularly after starting testosterone therapy. 5.14 hypercalcemia androgens, including kyzatrex™, should be used with caution in cancer patients at risk of hypercalcemia (and associated hypercalciuria). monitor serum calcium concentrations periodically during treatment with kyzatrex™ in these patients. 5.15 decreased thyroxine-binding globulin androgens, including kyzatrex™, may decrease concentrations of thyroxin-binding globulin, resulting in decreased total t4 serum concentrations and increased resin uptake of t3 and t4. free thyroid hormone concentrations remain unchanged, however, and there is no clinical evidence of thyroid dysfunction.

confirm the diagnosis of hypogonadism by ensuring that serum testosterone concentrations have been measured in the morning on at least two separate days and that these testosterone concentrations are below the normal range. 2.3 recommended dosage and administration individualize the dosage of kyzatrex™ based on the patient's serum testosterone concentration response to the drug. the recommended starting dose is 200 mg orally twice daily, once in the morning and once in the evening. take kyzatrex™ with food. dosage adjustment check serum testosterone concentrations 7 days after starting treatment or after dosage adjustment, 3 to 5 hours after the morning dose. adjust the kyzatrex™ dose as necessary as shown in table 1. thereafter, periodically monitor serum testosterone concentrations. the minimum recommended dose is 100 mg once daily in the morning. the maximum recommended dose is 400 mg twice daily. for total daily doses greater than 100 mg, administer the same dose in the morning and evening. table 1: kyzatrex™ dosage adjustment scheme serum testosterone concentration current kyzatrex™ dosage new kyzatrex™ dosage less than 460 ng/dl 100 mg with breakfast only 100 mg twice daily with meals 100 mg twice daily with meals 200 mg twice daily with meals 200 mg twice daily with meals 300 mg twice daily with meals 300 mg twice daily with meals 400 mg twice daily with meals 460 to 971 ng/dl no dosage change more than 971 ng/dl 400 mg twice daily with meals 300 mg twice daily with meals 300 mg twice daily with meals 200 mg twice daily with meals 200 mg twice daily with meals 100 mg twice daily with meals 100 mg twice daily with meals 100 mg with breakfast only 100 mg with breakfast only discontinue treatment

rmaceuticals at 1-833-949-5040 or fda at 1-800-fda-1088 or www.fda.gov/medwatch . 6.1 clinical trial experience because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. the safety of kyzatrex™ was evaluated in study mrs-tu-2019ext in 155 hypogonadal males [see clinical studies (14) ]. all patients initially received kyzatrex™ 200 mg orally twice daily. if needed, the dosage was titrated to 100 mg once daily in the morning or 100 mg, 300 mg, or 400 mg twice daily to achieve testosterone concentrations in the normal range . after the dosage titration period, patients continued their optimized dose for the remainder of the duration of the 6-month study. the mean duration of exposure was 168 days (range: 1 to 180 days). the median age was 52 years (range: 22 to 66 years); 77% were white, 19% were black, 3% were asian, and 2% were american indian, alaskan native or other. table 2 summarizes adverse reactions reported in ≥2% of patients in this 6-month study. table 2: adverse reactions in ≥ 2% of patients receiving kyzatrex™ in study mrs-tu-2019ext adverse reaction n = 155 n (%) hypertensión based upon blood pressure cuff measurements 4 (2.6) one (0.8%) patient who received kyzatrex™ experienced an adverse reaction (acne) that lead to premature discontinuation from the study. in a 12-month, open-label study in hypogonadal adult males (n=212) who received kyzatrex™ 200 mg once daily to 400 mg twice daily (n=202) the following additional adverse reactions were reported: headache, arthralgia, diarrhea, hemoglobin increased, anxiety, constipation, peripheral edema, and psa increased. blood pressure increases ambulatory (24-hour) and in-clinic (cuff) blood pressure changes from baseline for study mrs-tu-2019ext are presented in table 3 with 95% confidence intervals. no significant difference was observed between the 4-month and 6-month changes from baseline. table 3: blood pressure increases blood pressure change from baseline (95% ci) mm hg systolic diastolic 24-hour ambulatory 4 month 1.7 (0.3 to 3.1) 0.6 (-0.3 to 1.6) 6 month 1.8 (0.3 to 3.2) 0.6 (-0.4 to 1.6) in-clinic (blood pressure cuff) 4 month 2.7 (0.9 to 4.5) 1.5 (0.3 to 2.6) 6 month 2.4 (0.6 to 4.2) 1.7 (0.5 to 2.9) a total of 5 of 155 patients (3.2%) in study mrs-tu-2019ext began taking new antihypertensive medications after study start. no patient had a dose increase in their antihypertensive medication by the end of treatment. a history of antihypertensive treatment and diabetes mellitus at baseline were significant factors related to ambulatory sbp increases. table 4 presents the least squares mean estimates of change from baseline, with 95% ci's, for sub-populations of subjects at study start either with or without hypertensive treatment or with or without diabetes mellitus. table 4: ambulatory blood pressure increases by subject sub-group subgroups ambulatory systolic blood pressure change from baseline (95% ci), mm hg with hypertensive treatment at baseline (n=49) 4 month 3.4 (1.0 to 5.9) 6 month 3.1 (0.6 to 5.6) without hypertensive treatment at baseline (n=90) 4 month 0.7 (-1.0 to 2.4) 6 month 1.0 (-0.7 to 2.8) with diabetes at baseline (n=29) 4 month 3.0 (-0.2 to 6.2) 6 month 3.4 (0.2 to 6.7) without diabetes at baseline (n=110) 4 month 1.3 (-0.2 to 2.9) 6 month 1.3 (-0.3 to 2.9) heart rate increases kyzatrex™ increased mean (95%ci) 24-hour ambulatory heart rate by an average of 0.7 (-0.5 to 1.9) beats per minute (bpm) at 4 months and 1.9 (0.6 to 3.1) bpm at 6 months in study mrs-tu-2019ext. changes in heart rate were similar between patients with or without hypertension or diabetes. changes in heart rate with treatment were most prominent in the evening, 12 to 17 hours after the morning dose. increases in hemoglobin increases in hemoglobin were reported in 7 out of 155 patients (4.5%) in study mrs-tu2019ext. none of these increases led to premature discontinuation of kyzatrex™. hematocrit was not assessed in this study. headaches headaches were reported in 3 of 155 patients (1.9%) receiving kyzatrex™ in study mrstu-2019ext. increases in serum psa four out of 155 patients (2.6%) receiving kyzatrex™ in study mrs-tu-2019ext had an increase in psa from baseline greater than 1.4 ng/ml and two out of 155 patients (1.3%) had a psa of at least 4.0 ng/ml during study mrs-tu-2019ext. the mean (se) increase in psa from baseline was 0.15 (±0.04) ng/ml at 6 months (n=135). 6.2 postmarketing experience the following adverse reactions have been identified during post-approval use of testosterone. because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. cardiovascular disorders: myocardial infarction, stroke vascular disorders: venous thromboembolism

anticoagulant activity may be seen with androgens; therefore, more frequent monitoring of international normalized ratio (inr) and prothrombin time are recommended in patients taking warfarin, especially at the initiation and termination of androgen therapy. 7.3 corticosteroids the concurrent use of testosterone with corticosteroids may result in increased fluid retention and requires careful monitoring particularly in patients with cardiac, renal, or hepatic disease. 7.4 medications that may also increase blood pressure some prescription medications and nonprescription analgesic and cold medications contain drugs known to increase blood pressure. concomitant administration of these medications with kyzatrex™ may lead to additional increases in blood pressure [see warnings and precautions (5.1) ].

esus monkeys, pregnant animals received intramuscular injections of testosterone during the period of organogenesis. testosterone treatment at doses that were comparable to those used for testosterone replacement therapy resulted in structural impairments in both female and male offspring. structural impairments observed in females included increased anogenital distance, phallus development, empty scrotum, no external vagina, intrauterine growth retardation, reduced ovarian reserve, and increased ovarian follicular recruitment. structural impairments seen in male offspring included increased testicular weight, larger seminal tubular lumen diameter, and higher frequency of occluded tubule lumen. increased pituitary weight was seen in both sexes. testosterone exposure in utero also resulted in hormonal and behavioral changes in offspring. hypertension was observed in pregnant female rats and their offspring exposed to doses approximately twice those used for testosterone replacement therapy. 8.2 lactation risk summary kyzatrex™ is not indicated for use in females. 8.3 females and males of reproductive potential infertility males during treatment with large doses of exogenous androgens, including kyzatrex™, spermatogenesis may be suppressed through feedback inhibition of the hypothalamicpituitary-testicular axis [see warnings and precautions (5.8) and impairment of fertility (13.1) ] , possibly leading to adverse effects on semen parameters including sperm count. reduced fertility has been observed in some men taking testosterone replacement therapy. testicular atrophy, subfertility, and infertility have also been reported in men who abuse anabolic androgenic steroids [see drug abuse and dependence (9.2) ]. with either type of use, the impact on fertility may be irreversible. 8.4 pediatric use the safety and efficacy of kyzatrex™ in pediatric patients less than 18 years old have not been established. kyzatrex™ is not recommended for use in patients less than 18 years of age because of the potential for acceleration of bone age and premature closure of epiphyses. 8.5 geriatric use clinical studies of kyzatrex™ did not include any patients 65 years of age and older. therefore, it cannot be determined whether these patients respond differently from younger adult patients. additionally, there are insufficient long-term safety data in geriatric patients to assess the potentially increased risk of cardiovascular disease and prostate cancer. geriatric patients treated with androgens including kyzatrex™ may be at risk for worsening of signs and symptoms of bph [see warnings and precautions (5.4) ] .

ed for testosterone replacement therapy resulted in structural impairments in both female and male offspring. structural impairments observed in females included increased anogenital distance, phallus development, empty scrotum, no external vagina, intrauterine growth retardation, reduced ovarian reserve, and increased ovarian follicular recruitment. structural impairments seen in male offspring included increased testicular weight, larger seminal tubular lumen diameter, and higher frequency of occluded tubule lumen. increased pituitary weight was seen in both sexes. testosterone exposure in utero also resulted in hormonal and behavioral changes in offspring. hypertension was observed in pregnant female rats and their offspring exposed to doses approximately twice those used for testosterone replacement therapy.

t data to characterize an exposure-response relationship or time course of pharmacodynamics. 12.3 pharmacokinetics absorption kyzatrex™ was taken orally at a starting dose of 200 mg twice per day with meals in a multicenter, open-label trial in hypogonadal males. the dose was adjusted, as needed, on days 28 and 56 from a minimum dose of 100 mg (morning-only) to a maximum dose of 400 mg twice per day based on the plasma testosterone concentration obtained by a single blood draw collected 3 to 5 hours after the morning dose. the average daily naf/edta plasma testosterone concentration was 393.3 (±113.6) ng/dl after 90 days of treatment (normal eugonadal range in naf/edta plasma: 222-800 ng/dl. note that the titration scheme for use in clinical practice is based on serum total testosterone [see dosage and administration (2.2) ] . kyzatrex™ is expected to produce testosterone concentrations that approximate normal concentrations seen in healthy men. table 5 summarizes the pharmacokinetic (pk) parameters for plasma total testosterone in patients completing at least 90 days of kyzatrex™ treatment administered daily. table 5: naf-edta plasma testosterone c avg and c max at day 90 visit pk parameter plasma (n=130) pk = pharmacokinetic; c avg = 24-hour average concentration; c max = maximum concentration c avg (ng/dl) n 127 mean 393.3 sd 113.6 c max (ng/dl) n 130 mean 852.4 sd 311.3 figure 2 summarizes the mean plasma total testosterone profile at the final pk visit. figure 2: mean (±sem) concentration-time profile for naf-edta plasma total testosterone in kyzatrex™-treated patients at day 90 visit sem = standard error of the mean testosterone normal ranges: plasma = 222-800 ng/dl when kyzatrex™ was given with breakfast containing 16%, 33%, and 45% fat, the exposure (auc 0-24 hr ) of testosterone was increased by 37%, 87%, and 94%, respectively, compared to when given under fasted conditions. the primary efficacy and safety study was conducted under fed conditions regardless of the type of meals and the primary efficacy endpoint of achieving testosterone c avg in normal testosterone range was met. there was no effect on testosterone pk when kyzatrex™ was administered with 20% alcohol along with a high-fat meal versus a high-fat meal alone. figure 2 distribution circulating testosterone is primarily bound in serum to sex hormone-binding globulin (shbg) and albumin. approximately 40% of testosterone in plasma is bound to shbg, 2% remains unbound (free), and the rest is loosely bound to albumin and other proteins. metabolism the androgenic activity of testosterone undecanoate occurs after the ester bond linking the testosterone to the undecanoic acid is cleaved by endogenous non-specific esterases. undecanoic acid is metabolized like all fatty acids via the beta-oxidation pathway. testosterone is metabolized to various 17-keto steroids through two different pathways. the major active metabolites of testosterone are dihydrotestosterone (dht) and estradiol. excretion about 90% of a dose of testosterone given intramuscularly is excreted in the urine as glucuronic and sulfuric acid conjugates of testosterone and its metabolites. about 6% of a dose is excreted in the feces, mostly in the unconjugated form. inactivation of testosterone occurs primarily in the liver.

days of kyzatrex™ treatment administered daily. table 5: naf-edta plasma testosterone c avg and c max at day 90 visit pk parameter plasma (n=130) pk = pharmacokinetic; c avg = 24-hour average concentration; c max = maximum concentration c avg (ng/dl) n 127 mean 393.3 sd 113.6 c max (ng/dl) n 130 mean 852.4 sd 311.3 figure 2 summarizes the mean plasma total testosterone profile at the final pk visit. figure 2: mean (±sem) concentration-time profile for naf-edta plasma total testosterone in kyzatrex™-treated patients at day 90 visit sem = standard error of the mean testosterone normal ranges: plasma = 222-800 ng/dl when kyzatrex™ was given with breakfast containing 16%, 33%, and 45% fat, the exposure (auc 0-24 hr ) of testosterone was increased by 37%, 87%, and 94%, respectively, compared to when given under fasted conditions. the primary efficacy and safety study was conducted under fed conditions regardless of the type of meals and the primary efficacy endpoint of achieving testosterone c avg in normal testosterone range was met. there was no effect on testosterone pk when kyzatrex™ was administered with 20% alcohol along with a high-fat meal versus a high-fat meal alone. figure 2 distribution circulating testosterone is primarily bound in serum to sex hormone-binding globulin (shbg) and albumin. approximately 40% of testosterone in plasma is bound to shbg, 2% remains unbound (free), and the rest is loosely bound to albumin and other proteins. metabolism the androgenic activity of testosterone undecanoate occurs after the ester bond linking the testosterone to the undecanoic acid is cleaved by endogenous non-specific esterases. undecanoic acid is metabolized like all fatty acids via the beta-oxidation pathway. testosterone is metabolized to various 17-keto steroids through two different pathways. the major active metabolites of testosterone are dihydrotestosterone (dht) and estradiol. excretion about 90% of a dose of testosterone given intramuscularly is excreted in the urine as glucuronic and sulfuric acid conjugates of testosterone and its metabolites. about 6% of a dose is excreted in the feces, mostly in the unconjugated form. inactivation of testosterone occurs primarily in the liver.

lity. in untreated female rats mated with males receiving 2 times the maximum recommended human daily dose (mrhdd) of kyzatrex™ (based on mean auc exposure to testosterone), the number of impregnated females was reduced, fertility was significantly lower, and pre-implantation loss was significantly higher compared to the control group. there was no impairment of fertility in males receiving an equivalent dose of kyzatrex™ to the mrhdd. 13.2 animal toxicology and/or pharmacology a 3-month repeat-dose oral toxicity study in male eugonadal dogs was conducted to evaluate whether phytosterol esters present in the kyzatrex™ formulation influenced target organ toxicity due to their structural similarities to sex steroids like testosterone. kyzatrex™ doses 2 times the mrhdd (based on mean auc exposure to testosterone) produced similar effects on androgen-responsive tissues as testosterone undecanoate without phytosterol esters. these included mild to marked effects on the testes (decreased size, germ cell depletion, leydig cell atrophy), epididymides (aspermia), adrenal glands (vacuolation in the zona fasciculata) and prostate (increased size and glandular hypertrophy/hyperplasia). following a 4-week treatment-free period, findings in the testes, epididymides, and adrenal glands were not fully reversible at doses of 2 times the mrhdd of kyzatrex™ as compared to treatment with the excipients alone, including phytosterol esters. reversibility was not assessed in testosterone undecanoate groups without phytosterol esters.

rats mated with males receiving 2 times the maximum recommended human daily dose (mrhdd) of kyzatrex™ (based on mean auc exposure to testosterone), the number of impregnated females was reduced, fertility was significantly lower, and pre-implantation loss was significantly higher compared to the control group. there was no impairment of fertility in males receiving an equivalent dose of kyzatrex™ to the mrhdd.

native or other. primary efficacy results are summarized in table 6. table 6: proportion of patients in study mrs-tu-2019ext with average plasma total testosterone in the normal range (222-800 ng/dl) on day 90 parameter n=139 c avg = 24-hour average concentration patients (%) with testosterone, c avg (ng/dl), 222-800 ng/dl 122 (88%) 95% confidence interval (82%, 93%) secondary endpoints were the percentage of patients with a maximum total testosterone concentration (c max ) meeting three predetermined limits: less than or equal to 1.5 times the upper limit of normal range (uln) (1200 ng/dl), between 1.8 and 2.5 times uln (1440-2000 ng/dl), and greater than 2.5 times uln (2000 ng/dl). the percentage of patients who received kyzatrex™ and had testosterone cmax threshold less than or equal to 1200 ng/dl, between 1440 and 2000 ng/dl, and greater than 2000 ng/dl at the final pk visit were 88%, 4%, and 0%, respectively.

re and humid conditions. dispose of unused kyzatrex™ via a take-back option. if a take-back option is unavailable, follow fda instructions at www.fda.gov/drugdisposal.

thromboembolic events. advise patients about the importance of completing laboratory testing as instructed by their health care provider while on kyzatrex™ [see warnings and precautions (5.2) ]. worsening of benign prostatic hyperplasia (bph) and potential risk of prostate cancer advise patients that kyzatrex™ can cause increased symptoms of bph and can increase the risk for prostate cancer. advise patients to contact their health care provider if they have any prostate-related symptoms [see warnings and precautions (5.4) ]. edema advise patients that kyzatrex™ can cause edema in patients with preexisting cardiac, renal, or hepatic disease. advise patients to notify their health care provider if edema develops or worsens [see warnings and precautions (5.10) ]. sleep apnea advise patients that kyzatrex™ can worsen sleep apnea especially in patients with risk factors such as obesity or chronic lung diseases ™ [see warnings and precautions (5.11) ]. gynecomastia advise patients that kyzatrex™ can cause gynecomastia [see warnings and precautions (5.12) ]. administration instructions advise patients to take kyzatrex™ with food [see dosage and administration (2.3) ].